BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Net Asset Quality Index
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Net Asset Quality Index of 72.7% as of December 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €73.80 Billion minus total liabilities of €20.17 Billion yields net assets of €53.63 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See BEXIMCO PHARMA.GDR REGS 1 defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
BEXIMCO PHARMA.GDR REGS 1 Net Asset Quality Index Over Time (2021–2024)
This chart shows how BEXIMCO PHARMA.GDR REGS 1's Net Asset Quality Index has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the index stands at 72.7%, representing net assets of €53.63 Billion against total assets of €73.80 Billion EUR. Explore R2WA cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below presents the year-by-year Net Asset Quality Index for BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024, covering 4 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see BEXIMCO PHARMA.GDR REGS 1 (R2WA) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 74.8% | €51.90 Billion | €69.34 Billion | €17.44 Billion | ▲ +6.0 pp |
| 2023 | 68.9% | €47.62 Billion | €69.16 Billion | €21.54 Billion | ▲ +1.4 pp |
| 2022 | 67.5% | €44.64 Billion | €66.15 Billion | €21.51 Billion | ▼ -4.0 pp |
| 2021 | 71.5% | €37.36 Billion | €52.25 Billion | €14.88 Billion | — |